Discordant tumor response in the treatment of ALK-rearranged non-small cell lung cancer leads to the diagnosis of synchronous multiple primary lung cancer

• 作者: Benny Johnson Maged Khalil
• 来源期刊: 临床医学病理报告(英文)
• 学科: 医学
• 关键词: Non-Small Cell LUNG CANCER CRIZOTINIB SYNCHRONOUS Multiple Primary LUNG CANCER EML4-ALK Fusion Gene
• 年，卷（期）: 2013,（1）
• 页码范围: 16-19
• 页数: 4页
• 分类号: R73

摘要

The advent of targeted molecular therapy against the EML4-ALK fusion gene is the latest therapeutic intervention for a subset of patients with non-small cell lung cancer (NSCLC). Crizotinib (Xalkori) is an orally available small molecule tyrosine kinase inhibitor proven in clinical trials to significantly impact progression free survival and overall response rate. We present a case of a 56-year-old male with NSCLC whose lack of a positive treatment response to this therapy led to the clinical suspicion and identification of the underdiagnosed entity known as synchronous multiple primary lung cancer (SMPLC).